ClinicalTrials.gg
TerminatedNCT04237116pINPOINtUpdated Feb 29, 2024Results posted

A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)

A Phase 3 interventional study of Investigational Arm - secukinumab and Control Arm - placebo in Plaque Psoriasis and Non-alcoholic Fatty Liver Disease, sponsored by Novartis Pharmaceuticals. Terminated at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Low enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 89 studies in Non-alcoholic Fatty Liver Disease with a site in Germany — 14 open to participants now, 21 under way, 8 of them phase 3. Non-alcoholic Fatty Liver Disease · Germany.

Enrollment
74th of 75
10 · median 186
Started
2020
with 6 others
Phase 3
17 of 89
5 open now
Registered
56th of 89
by date
Lead sponsor
5 of 89
Novartis Pharmaceuticals

Among the 89 studies in Non-alcoholic Fatty Liver Disease with a site in Germany, this one is the 74th largest by enrollment of the 75 interventional ones that give a count, is one of 7 that started in 2020, is one of 17 in phase 3, and was the 56th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

14 of the 89 studies in Non-alcoholic Fatty Liver Disease with a site in Germany are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Non-alcoholic Fatty Liver Disease with a site in Germany, or all of them as a file.
02

Study summary

The aim of this study was to assess the therapeutic efficacy of secukinumab on the psoriatic skin and to explore the anti-inflammatory (reduction of hepatic inflammation and cell damage), anti-steatotic (reduction of hepatic triglyceride content) and anti-fibrotic (reduction of hepatic fibrosis) effects of secukinumab in patients with psoriasis and coexisting non-alcoholic fatty liver disease (NAFLD).

Read the detailed description

Primary outcome measure is Percentage of participants achieving ≥ 90% improvement (reduction) in PASI score compared to Baseline. Psoriasis Area and Severity Index (PASI) 90 response is defined as ≥ 90% improvement (reduction) in score compared to Baseline. It is a composite score where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. Score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. Primary analysis was planned to be performed comparing treatments with respect to the primary efficacy variable in a logistic regression model. It was planned to present the Odds Ratio and its 95%-confidence interval and p-value. Planned null hypothesis to be rejected was that the Odds Ratio of a PASI90 response for patients with secukinumab vs. patients with placebo is ≥1 after 12 weeks. Due to premature termination and limited number of treated patients with available data (7 in the secukinumab group and 3 in the placebo group), the extent of the originally planned statistical analyses of efficacy data was limited to descriptive summaries (absolute values per visit and changes from baseline; presented as mean and SD) for the score.

03

Conditions studied

  • Plaque Psoriasis
  • Non-alcoholic Fatty Liver Disease

Keywords

  • plaque psoriasis
  • NAFLD
  • NASH
  • PASI
  • secukinumab
  • non-alcoholic fatty liver disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male/female patients, 18 years or older
  • Moderate to severe plaque-type psoriasis, candidate for systemic therapy
  • Diagnosis of NAFLD by either ultrasound at Screening or liver histology within 6 months before Baseline
  • > 25 kg/ m 2
  • 1.2 to 3.0 ×
  • MRI confirmed Liver fat ≥ 8% at Screening

Exclusion criteria

Exclusion Criteria:

  • Forms of psoriasis other than chronic plaque-type Psoriasis
  • Drug induced psoriasis
  • Pregnant or nursing (lactating) women
  • Women of child bearing potential unless they are using effective methods of
  • Ongoing use of prohibited treatments
  • Previous treatment with biological drug targeting IL-17 or the IL-17 receptor
  • Past medical history record of infection with (HIV), or prior to Screening
  • Unstable weight over the last 6 months prior to Screening.
  • Type I diabetes, or uncontrolled diabetes (Type I or Type II) defined as HbAlc ≥ 10% at screening.
  • Evidence of hepatic decompensation or severe liver impairment or cirrhosis
  • History of liver transplantation or planned liver transplant or biliary diversion.
  • Presence or history of other liver disease
  • Current, or history of, significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening
  • Prior or planned bariatric surgery
  • Inability or unwillingness to undergo MRI of the abdomen
  • Past medical history record of infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C prior to Screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Investigational Arm - secukinumab

    secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind

    Biological: Investigational Arm - secukinumab

  • Placebo comparator
    Control Arm - placebo

    placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20

    Biological: Control Arm - placebo

Interventions

  • secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind

    Also known as: AIN457

  • BiologicalControl Arm - placebo

    placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20

    Also known as: AIN457

06

What researchers measure

Primary outcomes

  1. Mean and SD Change From Baseline of PASI Score up to Week 12

    Psoriasis Area and Severity Index (PASI) 90 response is defined as ≥ 90% improvement (reduction) in score compared to Baseline. It is a composite score where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. Score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. Primary analysis was planned to be performed comparing treatments with respect to the primary efficacy variable in a logistic regression model.

    Time frame: 12 weeks

Secondary outcomes

  1. Serum Alanine Aminotransferase (ALT) Level

    ALT is an enzyme that the liver releases when it becomes inflamed or damaged. ALT level measures liver function Parameter. Normal range of values for ALT is about 7 to 56 units per liter (U/L). Higher levels of ALT in the blood indicate more liver problems. Due to the premature study termination and the limited number of treated patients with available data (7 patients in the secukinumab group and 3 patients in the placebo group), the extent of the originally planned statistical analyses of efficacy data was limited to descriptive summaries (absolute values per visit and changes from baseline; presented as mean and standard deviation) for the ALT score.

    Time frame: 12 weeks

  2. Mean and SD of DLQI at Week 12

    Dermatology Life Quality Index (DLQI) is calculated by summing the score of each domain resulting in a maximum of 30 and a minimum of 0. The higher the score, the more Quality of Life was impaired. Meaning of DLQI Scores: 0-1 = no effect at all on patient's life, 2-5 = small effect on patient's life, 6-10 = moderate effect on patient's life, 11-20= very large effect on patient's life, 21-30 = extremely large effect on patient's life. Due to the premature study termination and the limited number of treated patients with available data (7 patients in the secukinumab group and 3 patients in the placebo group), the extent of the originally planned statistical analyses of efficacy data was limited to descriptive summaries (absolute values per visit and changes from baseline; presented as mean and standard deviation) for DLQI scores.

    Time frame: 12 weeks

07

Results

Posted Feb 8, 2024
Limitations and caveats
Due to premature termination and limited number of treated patients (7 for secukinumab group and 3 in placebo), the extent of originally planned statistical analyses of efficacy was limited to descriptive summaries (absolute values per visit and changes from baseline; presented as mean and standard deviation) for the PASI score, ALT values, and DLQI scores.

Participant flow

7 German centers and 1 Spanish center had randomized 8 and 2 patients, respectively. Patients who were still in the study when the sponsor terminated the study were counted as 'non-completers'.

Participant flow — Overall Study
MilestoneInvestigational Arm - SecukinumabControl Arm - Placebo
Started73
Completed31
Not completed42
Withdrew: Adverse event01
Withdrew: Study terminated by sponsor41

Outcome measures

SecondarySerum Alanine Aminotransferase (ALT) Level

ALT is an enzyme that the liver releases when it becomes inflamed or damaged. ALT level measures liver function Parameter. Normal range of values for ALT is about 7 to 56 units per liter (U/L). Higher levels of ALT in the blood indicate more liver problems. Due to the premature study termination and the limited number of treated patients with available data (7 patients in the secukinumab group and 3 patients in the placebo group), the extent of the originally planned statistical analyses of efficacy data was limited to descriptive summaries (absolute values per visit and changes from baseline; presented as mean and standard deviation) for the ALT score.

Time frame:
12 weeks
Reported as:
Mean · U/L
Serum Alanine Aminotransferase (ALT) Level
U/LInvestigational Arm - SecukinumabControl Arm - Placebo
Baseline60.5 ± 35.7389.0 ± 15.56
Week 1243.3 ± 12.7685.5 ± 20.51
SecondaryMean and SD of DLQI at Week 12

Dermatology Life Quality Index (DLQI) is calculated by summing the score of each domain resulting in a maximum of 30 and a minimum of 0. The higher the score, the more Quality of Life was impaired. Meaning of DLQI Scores: 0-1 = no effect at all on patient's life, 2-5 = small effect on patient's life, 6-10 = moderate effect on patient's life, 11-20= very large effect on patient's life, 21-30 = extremely large effect on patient's life. Due to the premature study termination and the limited number of treated patients with available data (7 patients in the secukinumab group and 3 patients in the placebo group), the extent of the originally planned statistical analyses of efficacy data was limited to descriptive summaries (absolute values per visit and changes from baseline; presented as mean and standard deviation) for DLQI scores.

Time frame:
12 weeks
Reported as:
Mean · Units on a scale
Mean and SD of DLQI at Week 12
Units on a scaleInvestigational Arm - SecukinumabControl Arm - Placebo
Baseline11.3 ± 5.568.0 ± 8.49
Week 120.3 ± 0.507.0 ± 8.49
PrimaryMean and SD Change From Baseline of PASI Score up to Week 12

Psoriasis Area and Severity Index (PASI) 90 response is defined as ≥ 90% improvement (reduction) in score compared to Baseline. It is a composite score where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. Score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. Primary analysis was planned to be performed comparing treatments with respect to the primary efficacy variable in a logistic regression model.

Time frame:
12 weeks
Reported as:
Mean · Units on a scale
Mean and SD Change From Baseline of PASI Score up to Week 12
Units on a scaleInvestigational Arm - SecukinumabControl Arm - Placebo
Baseline (n=7,3)15.7 ± 4.2215.9 ± 3.39
Week 12 (n=4,2)0.8 ± 1.1413.4 ± 0.35

Adverse events

Collected over Adverse Events (AEs) and Serious Adverse Events were collected after signature of the informed consent form until 30 days after last dose of study treatment, and up to 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab 300mg0/7 (0%)1/7 (14.3%)4/7 (57.1%)
Placebo0/3 (0%)0/3 (0%)2/3 (66.7%)
Most frequent serious events
Most frequent serious events
EventSecukinumab 300mgPlacebo
Aspartate aminotransferase increasedInvestigations1/70/3
Most frequent other events
Showing 10 of 19
Most frequent other events
EventSecukinumab 300mgPlacebo
Haemorrhoids thrombosedGastrointestinal disorders0/71/3
Alanine aminotransferase increasedInvestigations0/71/3
Blood creatine phosphokinase increasedInvestigations1/71/3
HypertriglyceridaemiaMetabolism and nutrition disorders0/71/3
MyalgiaMusculoskeletal and connective tissue disorders0/71/3
HeadacheNervous system disorders1/71/3
PsoriasisSkin and subcutaneous tissue disorders0/71/3
NasopharyngitisInfections and infestations2/70/3
HypothyroidismEndocrine disorders1/70/3
Abdominal pain upperGastrointestinal disorders1/70/3

Baseline characteristics

Full Analysis Set

Age, Categorical
Age, Categorical(Participants)Investigational Arm - SecukinumabControl Arm - PlaceboTotal
<=18 years000
Between 18 and 65 years7310
>=65 years000
Age, Continuous
Age, Continuous(years)Investigational Arm - SecukinumabControl Arm - PlaceboTotal
Mean41.6 ± 11.832.0 ± 16.838.7 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Investigational Arm - SecukinumabControl Arm - PlaceboTotal
Female404
Male336
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Investigational Arm - SecukinumabControl Arm - PlaceboTotal
White7310
08

Study locations

8 sites
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Muenchen, 80377, Germany
  • Novartis Investigative Site
    Potsdam, 14467, Germany
  • Novartis Investigative Site
    Stuttgart, 70178, Germany
  • Novartis Investigative Site
    Tuebingen, 72076, Germany
  • Novartis Investigative Site
    Wuerzburg, 97080, Germany
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46014, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Jun 2021, 16 months.

Results were first posted in Feb 2024, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2020
First posted
Jan 23, 2020
StartActual
Feb 19, 2020
Primary completionActual
Jun 29, 2021
CompletionActual
Jul 23, 2021
Results first posted
Feb 8, 2024
Last update
Feb 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04237116
Responsible party
Sponsor
First posted
Jan 23, 2020
Start date
Feb 19, 2020
Primary completion
Jun 29, 2021
Completion
Jul 23, 2021
Results posted
Feb 8, 2024
Last update
Feb 29, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion